Complement Factor H (CFH) is a pivotal regulator of the complement system, integral to maintaining immune homeostasis and protecting host tissues from undue complement‐mediated damage. By inhibiting ...

RGC-32, or Response Gene to Complement 32, plays a pivotal role in mediating cellular responses following complement activation. Acting as a regulator of the cell cycle, RGC-32 is implicated in ...

Commit Biologics (“Commit”), a biotechnology company pioneering complement system activation and backed by €21.5 million in ...

A team has identified a previously unknown phase of the immune response. The results challenge long-standing assumptions about the process called 'T-cell priming'. These new insights have significant ...

For years, patients with C3G and IC-MPGN had few options to stop the progression toward kidney failure. Now a new class of FDA-approved C3 inhibitors that targets the root of the complement system can ...

Cancer immunotherapy has transformed the treatment landscape for multiple malignancies; however, its clinical efficacy remains limited in many tumors due to ...

Harvard Medical School scientists have identified a key protein in the human immune system that drives inflammatory and autoimmune conditions when it turns against the body. The protein, Granzyme K, ...

Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a unique potential to selectively target malignant cells while sparing normal tissues.

A new microfluidic technology that leverages immune cell behavior is set to transform cancer monitoring, thanks to researchers at UNIST. Led by Professor Joo Hun Kang in the Department of Biomedical ...